PMGC subsidiary NorthStrive Biosciences announces positive Phase III results
The AI-driven program with Yuva Biosciences identified four compounds that increased ANT1 expression in human skeletal muscle cells.
See the latest news and media coverage for PMGC. We track all announcements, press releases, and industry mentions in real time, all in one place.
Diversified holding company acquiring manufacturing businesses
pmgcholdings.comLast updated
In short: PMGC aggressively expanded its aerospace and defense portfolio through strategic acquisitions, multi-million dollar financing, and licensing.
The AI-driven program with Yuva Biosciences identified four compounds that increased ANT1 expression in human skeletal muscle cells.
The target is AS9100 compliant, serves aerospace, defense, and semiconductor markets, with $5.46M revenue in 2025.
The $4.5M cash deal adds an AS9100D-certified aerospace manufacturer with $5M revenue and $610K adjusted EBITDA.
The patent covers formulations and dosing for muscle loss from GLP-1 use, sarcopenia, disuse atrophy, and neurological disorders.
PMGC Holdings Inc. ELAB shares jumped 37.74% to $1.46 in overnight trading on Thursday as the biopharmaceutical company disclosed a merger between two wholly owned...
Detailed price information for Pmgc Holdings Inc (ELAB-Q) from The Globe and Mail including charting and trades.
The U.S. small and micro modular reactor (SMR/MMR) market is experiencing rapid growth, driven by energy security needs, data center demand, and federal support for...
Binding term sheet for an exclusive, worldwide, sublicensable license in the aerospace and defense field to a granted U.S. patent covering autonomous, buoyancy-assisted transport of...
Track PMGC and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.